Guardant Health, Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 6, 2023 and accepted by EDGAR at Nov 6, 2023, 16:58 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-01 to 2023-09-30 | $143.0m | us-gaap:Revenues |
| Revenue | 9 months2023-01-01 to 2023-09-30 | $408.9m | us-gaap:Revenues |
| Research and development | 3 months2023-07-01 to 2023-09-30 | $93.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-01-01 to 2023-09-30 | $277.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-07-01 to 2023-09-30 | −$113.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-01-01 to 2023-09-30 | −$367.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-07-01 to 2023-09-30 | $644.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2023-01-01 to 2023-09-30 | $1.9m | us-gaap:InterestExpense |
| Income tax | 3 months2023-07-01 to 2023-09-30 | $490.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-01-01 to 2023-09-30 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | −$86.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | −$292.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | −$0.73 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-01-01 to 2023-09-30 | −$2.66 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | −$0.73 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-01-01 to 2023-09-30 | −$2.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 117,736,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-01 to 2023-09-30 | 109,791,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | −$246.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-01-01 to 2023-09-30 | $16.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-09-30 | $457.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $1.35bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $1.80bn | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $226.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $1.57bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-09-30 | $228.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001576280-23-000187. Last ingested by Listed: Nov 5, 2026, 17:05 ET. Listed shows no prices and gives no investment advice.